<DOC>
	<DOCNO>NCT02013830</DOCNO>
	<brief_summary>This study evaluate efficacy safety oral Xeloda ( capecitabine ) plus intravenous Avastin ( bevacizumab ) patient advance metastatic liver cancer . The anticipated time study treatment 3-12 month .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Xeloda ( Capecitabine ) Patients With Advanced Metastatic Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>adult patient &gt; =18 year age ; advanced metastatic liver cancer ; &gt; =1 measurable lesion . current radiotherapy , chemotherapy , experimental therapy ; prior cytotoxic chemotherapy ; major surgery , open biopsy , traumatic injury within 28 day study entry ; history malignancy last 5 year , cutaneous basal cell cancer situ cervical cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>